BACKGROUND: Booster doses of SARS-CoV-2 mRNA vaccines are commonly used in kidney transplant recipients (KTRs). However, there is uncertainty regarding the waning of vaccination responses and immunological safety in KTRs. METHODS: A total of 123 KTRs were included in the final analysis of this prospective observational cohort study. The aim was to evaluate the immunogenicity and immunological safety. SARS-CoV-2 antispike IgG antibodies and anti-HLA antibodies were measured at baseline and then at months 3, 6, and 12 after vaccination with the first booster dose (ie, the third vaccine dose). Antibodies against S1 and S2 subunits of SARS-CoV-2 were evaluated using an immunochemiluminescent assay (cutoff 9.5 AU/mL, sensitivity 91.2%, and specificity 90.2%). Anti-HLA antibodies were analyzed using single-antigen bead technology. RESULTS: Seroconversion was reached in 65% of KTRs previously nonresponding to 2-dose mRNA vaccination; the overall seroconversion rate 3 mo after the first booster dose was 83%. Vaccination induced a durable humoral response, and the antibody levels were stable during the 12-mo study follow-up. Higher age (exponentiated beta coefficient [eβ] 0.97; 95% confidence interval [CI], 0.943-0.997) and a full dose of mycophenolate (eβ 0.296; 95% CI, 0.089-0.984) were negatively associated with SARS-CoV-2 IgG antibody levels, whereas better graft function (eβ1.021; 95% CI, 1.005-1.037) was associated positively. There were no systematic signs of anti-HLA antibody development after vaccination. However, during the follow-up, there was a nonsignificant signal of an increase in anti-HLA antibodies in those who developed COVID-19. CONCLUSIONS: Additional booster doses of SARS-CoV-2 mRNA vaccines induce durable antibody response even in a large subset of previous nonresponders and are not associated with the risk of allosensitization. Furthermore, a signal linking COVID-19 to the development of anti-HLA antibodies was observed, and this should be confirmed and further examined (NCT05483725).

Department of Clinical and Transplant Immunology Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Nephrology Institute for Clinical and Experimental Medicine Prague Czech Republic

Immunogenetics Department Institute for Clinical and Experimental Medicine Prague Czech Republic

Information Technology Department Institute for Clinical and Experimental Medicine Prague Czech Republic

Transplant Laboratory Institute for Clinical and Experimental Medicine Prague Czech Republic

Zobrazit více v PubMed

Ying T, Shi B, Kelly PJ, et al. . Death after kidney transplantation: an analysis by era and time post-transplant. J Am Soc Nephrol. 2020;31:2887–2899. PubMed PMC

Magicova M, Zahradka I, Fialova M, et al. . Determinants of immune response to anti–SARS-CoV-2 mRNA vaccines in kidney transplant recipients: a prospective cohort study. Transplantation. 2022;106:842–852. PubMed PMC

Sattler A, Schrezenmeier E, Weber UA, et al. . Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. J Clin Invest. 2021;131:e150175. PubMed PMC

Zahradka I, Petr V, Modos I, et al. . Association between SARS-CoV-2 messenger RNA vaccines and lower infection rates in kidney transplant recipients: a registry-based report. Ann Intern Med. 2022;175:961–968. PubMed PMC

Aslam S, Adler E, Mekeel K, et al. . Clinical effectiveness of COVID‐19 vaccination in solid organ transplant recipients. Transpl Infect Dis. 2021;23:e13705. PubMed PMC

Levin EG, Lustig Y, Cohen C, et al. . Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385:e84. PubMed PMC

Petr V, Zahradka I, Modos I, et al. . First booster of SARS-COV-2 mRNA vaccine is not associated with alloimmunization and subclinical injury of kidney allograft. Transplantation. 2022;107:e62–e64. PubMed

Dudley MZ, Halsey NA, Omer SB, et al. . The state of vaccine safety science: systematic reviews of the evidence. Lancet Infect Dis. 2020;20:e80–e89. PubMed

Locke JE, Zachary AA, Warren DS, et al. . Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant. 2009;9:2136–2139. PubMed

Dendle C, Stuart RL, Polkinghorne KR, et al. . Seroresponses and safety of 13-valent pneumococcal conjugate vaccination in kidney transplant recipients. Transpl Infect Dis. 2018;20:e12866. PubMed

Mulley WR, Dendle C, Ling JEH, et al. . Does vaccination in solid-organ transplant recipients result in adverse immunologic sequelae? A systematic review and meta-analysis. J Heart Lung Transplant. 2018;37:844–852. PubMed

Goldman M. The safety of anti-SARS-CoV-2 vaccines: vigilance is still required. J Clin Med. 2022;11:1248. PubMed PMC

Komenda M, Bulhart V, Karolyi M, et al. . Complex reporting of the COVID-19 epidemic in the Czech Republic: use of an interactive web-based app in practice. J Med Internet Res. 2020;22:e19367. PubMed PMC

Süsal C, Wettstein D, Döhler B, et al. ; Collaborative Transplant Study Report. Association of kidney graft loss with De Novo produced donor-specific and non-donor-specific HLA antibodies detected by single antigen testing. Transplantation. 2015;99:1976–1980. PubMed

Al Jurdi A, Gassen RB, Borges TJ, et al. . Non-invasive monitoring for rejection in kidney transplant recipients after SARS-CoV-2 mRNA vaccination. Front Immunol. 2022;13:838985. PubMed PMC

Reed EF, Rao P, Zhang Z, et al. . Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA: CTOT HLA antibody standardization. Am J Transplant. 2013;13:1859–1870. PubMed PMC

Eurotransplant. Virtual PRA calculator. Available at https://www.etrl.org/vPRA.aspx. Accessed September 25, 2023.

Rodrigues CMC, Plotkin SA. Impact of vaccines; health, economic and social perspectives. Front Microbiol. 2020;11:1526. PubMed PMC

Pegu A, O’Connell SE, Schmidt SD, et al. ; mRNA-1273 Study Group. Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants. Science. 2021;373:1372–1377. PubMed PMC

Zhuang C, Liu X, Chen Q, et al. . Protection duration of COVID-19 vaccines: waning effectiveness and future perspective. Front Microbiol. 2022;13:828806. PubMed PMC

Naaber P, Tserel L, Kangro K, et al. . Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021;10:100208. PubMed PMC

Greinacher A, Thiele T, Warkentin TE, et al. . Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384:2092–2101. PubMed PMC

Blumberg EA, Brozena SC, Groover JE, et al. . Immunogenicity of pneumococcal vaccine (PV) in heart transplant recipients (HTR). Clin Infect Dis. 1997;25:464–464. PubMed

Katerinis I, Hadaya K, Duquesnoy R, et al. . De Novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients: H1N1 immunization and anti-HLA antibody. Am J Transplant. 2011;11:1727–1733. PubMed

Brakemeier S, Schweiger B, Lachmann N, et al. . Immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix(R)) in renal transplant recipients. Nephrol Dial Transplant. 2012;27:423–428. PubMed

Cordero E, Manuel O. Influenza vaccination in solid-organ transplant recipients. Curr Opin Organ Transplant. 2012;17:601–608. PubMed

Hirzel C, Kumar D. Influenza vaccine strategies for solid organ transplant recipients. Curr Opin Infect Dis. 2018;31:309–315. PubMed

Candon S, Thervet E, Lebon P, et al. . Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients. Am J Transplant. 2009;9:2346–2354. PubMed

Schinstock CA, Mannon RB, Budde K, et al. . Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 Expert Consensus from the Transplantion Society Working Group. Transplantation. 2020;104:911–922. PubMed PMC

Caillard S, Thaunat O. COVID-19 vaccination in kidney transplant recipients. Nat Rev Nephrol. 2021;17:785–787. PubMed PMC

Zahradka I, Petr V, Jakubov K, et al. . Early referring saved lives in kidney transplant recipients with COVID-19: a beneficial role of telemedicine. Front Med. 2023;10:1252822. PubMed PMC

Zobrazit více v PubMed

ClinicalTrials.gov
NCT05483725